Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
Even in the most controlled labs, balance performance can drift — electrostatics, air drafts, temperature shifts, or even the way samples are handled can quietly undermine your results...
Unlock the full potential of your LC-MS system with Thermo Scientific™ Chromeleon™ software features. This webinar will demonstrate the system suitability test with intelligent r...
Research in plant and animal genomics often involve complex genetic challenges that require tailored approaches. From addressing genetic complexity in aquaculture species to investigating tr...
Do you use pipettes in your daily work? Want to improve your pipetting accuracy? To eliminate the guesswork, METTLER TOLEDO Rainin developed Good Pipetting Practice™ (GPP™) as a...
BACKGROUND . Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to Acute Myeloid Leukemia (AM...